10X Genomics Q3 revenue beats expectations, net loss narrows

10x Genomics

06/11/2025 21:56

Overview

10X Genomics Q3 revenue of $149 mln beats analyst expectations

Company reports Q3 net loss of $27.5 mln, improved from prior year

Operating expenses fell 10% yr/yr, aiding reduction in net loss

Outlook

10x Genomics expects Q4 2025 revenue between $154 mln and $158 mln

Result Drivers

INSTRUMENT REVENUE DECLINE - Decrease in instrument revenue contributed to overall revenue decline

OPERATING EXPENSES - 10% decrease in operating expenses due to lower personnel and legal costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$149 mln
$142.50 mln (14 Analysts)
Q3 EPS
-$0.22
Q3 Net Income
-$27.5 mln
Q3 Gross Margin
67%
Q3 Operating Income
-$32.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for 10X Genomics Inc is $15.00, about 10.1% above its November 5 closing price of $13.49

Press Release: ID:nPn2Lfntla

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)